Tactile Systems Earnings Call Signals Profitable Growth

Tactile Systems Technology ((TCMD)) has held its Q1 earnings call. Read on for the main highlights of the call.

Tactile Systems Technology’s latest earnings call struck an optimistic tone, as management highlighted robust revenue growth, expanding margins and a return to adjusted EBITDA profitability. While executives acknowledged new Medicare prior authorization rules and shifting margin mix as near‑term headwinds, they stressed that innovation, M&A and operational efficiencies are setting up a stronger long‑term trajectory.

Strong Top-Line Growth

Tactile Systems posted Q1 revenue of $75.3 million, up 23% year over year, underscoring broad-based demand across its portfolio. Lymphedema revenue grew 23% to $62.2 million and airway clearance sales climbed 22% to $13.0 million, reinforcing the company’s position in two attractive, underpenetrated segments.

Margin Expansion and Profitability Traction

Gross margin improved to 76.5%, roughly 250 basis points higher than a year earlier, reflecting better mix and operating discipline. Adjusted EBITDA swung to a $3.7 million profit from a small loss, lifting the margin to 4.9% and signaling that scaling revenues are starting to drop to the bottom line.

Raised Full-Year Guidance

Management raised its 2026 revenue outlook to a range of $360 million to $368 million, implying 9% to 12% annual growth with both lymphedema and airway businesses contributing. Adjusted EBITDA is projected between $49 million and $51 million, suggesting continued operating leverage despite higher investments and a slightly more complex margin profile.

Product and R&D Momentum

The company secured FDA 510(k) clearance for a next-generation AffloVest that is lighter, digitally connected and offers an improved fit, aimed at enhancing patient adherence and clinical outcomes. Flexitouch continued to benefit from Medicare coverage clarity and favorable reimbursement, with Medicare channel sales rising about 40% from the prior year.

Acquisition and Strategic Expansion

Tactile closed its acquisition of Lymphotech in February and reported that integration is tracking as planned, broadening its footprint in lymphedema care and related services. Lymphotech’s selection for a major federal funding program is already generating grant revenue, which is now baked into the company’s updated financial outlook.

Operational and Technology Improvements

The company accelerated deployment of an AI-enabled prior authorization platform before new Medicare rules took effect in April, seeking to mitigate administrative friction. Alongside upgrades in CRM and workflow tools, management noted higher sales territory productivity, better collections and a meaningful reduction in days sales outstanding.

Healthy Balance Sheet and Financial Flexibility

Tactile ended the quarter with roughly $75 million in cash and cash equivalents and no debt, providing ample flexibility to fund organic initiatives and share repurchases. This liquidity position, even after acquisition spending, is a key support for its multi-year growth and innovation agenda.

Medicare Prior Authorization Uncertainty and Execution Risk

New Medicare prior authorization requirements for pneumatic compression devices took effect in mid-April, and the company has only a few weeks of early experience. Management flagged variability across regional contractors and expects some short-term disruption to order cadence, with a softer near-term ramp before processes normalize.

Higher Operating Expenses

GAAP operating expenses rose 19% to $59.1 million, driven by higher sales and marketing, R&D and G&A as prior investments annualize and strategic spending continues. While these costs weigh on GAAP profitability, management framed them as necessary to sustain growth, launch new products and support integration initiatives.

Lymphotech Revenue Composition This Year

In the near term, Lymphotech is contributing mainly grant and service revenue, which carries lower margins than the core product business and dilutes profitability metrics. Management cited this mix shift as a key reason why adjusted EBITDA guidance is not rising as quickly as revenue expectations despite the acquisition.

Cash Position Decline and Reduced Interest Income

Cash fell to about $75 million from $83.4 million at year-end, reflecting the Lymphotech deal, share repurchases and normal seasonal items. Lower cash balances and prevailing rates pushed interest income down about 26% to $0.7 million, a modest drag on the bottom line relative to prior quarters.

Ongoing Net Loss

On a GAAP basis, Tactile reported a net loss of $1.8 million, or $0.08 per diluted share, which is 41% better than a year ago but still in negative territory. The gap between GAAP losses and positive adjusted EBITDA underscores the impact of noncash items and elevated investment on reported earnings.

Short-Term Revenue Cadence Uncertainty

Management cautioned that revenue progression this year is unlikely to be linear, given the learning curve around Medicare prior authorization for compression devices. They anticipate a relatively modest sequential step-up in the second quarter followed by a stronger rebound in the third quarter as documentation and approval patterns stabilize.

Forward-Looking Guidance and Outlook

For 2026, the company expects revenue between $360 million and $368 million, GAAP gross margins of 76% to 77% and operating expenses growing roughly 10% to 12% year over year. Management projects adjusted EBITDA of $49 million to $51 million alongside modest net interest income and normal tax rates, stressing disciplined spending while Medicare dynamics mature.

Tactile Systems’ earnings call painted a picture of a business gaining commercial momentum and profitability leverage while managing policy-driven uncertainty. Strong growth, product innovation and a solid balance sheet are offsetting execution and margin-mix risks, leaving investors with a cautiously constructive long-term story anchored by expanding exposure to chronic care markets.